# US Formulation Development Outsourcing Market

> US Formulation Development Outsourcing Market Research Report: Size, Share, Trend Analysis By Services (Pre Formulation Services, Formulation Optimization), By Dosage Form (Injectable, Oral, Topical, Inhaled, Others), By Applications (Oncology, Genetic Disorders, Neurology, Infectious Disease, Respiratory, Cardiovascular, Others) and By End Users (Pharmaceutical and Biopharmaceutical, Government, Academic Institutes) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.51%
- **2024:** $ 2,300 Million
- **2025:** $ 2,472.73 Million
- **2035:** $ 5,100 Million
- **Key Players:** Lonza Group (CH), Catalent (US), Boehringer Ingelheim (DE), Recipharm (SE), Famar (FR), Siegfried Holding (CH), Alcami (US), Aenova Group (DE), Vetter Pharma (DE)

**Report ID:** MRFR/MED/16493-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-formulation-development-outsourcing-market-18021

---

## Market Summary

## **US Formulation Development Outsourcing Market Overview**

As per MRFR analysis, the US Formulation Development Outsourcing Market Size was estimated at 1.62 (USD Billion) in 2023.The US Formulation Development Outsourcing Market Industry is expected to grow from 1.8(USD Billion) in 2024 to 4.2 (USD Billion) by 2035. The US Formulation Development Outsourcing Market CAGR (growth rate) is expected to be around 8.007% during the forecast period (2025 - 2035)

**Key US Formulation Development Outsourcing Market Trends Highlighted**

The US Formulation Development Outsourcing Market is experiencing a notable shift driven by various factors. One of the key market drivers is the increasing demand for innovative drug formulations and the need for cost-effective solutions. As pharmaceutical companies seek to reduce time to market and increase efficiency, outsourcing formulation development has become a strategic approach. Additionally, the rise of personalized medicine is pushing companies to look for partners that can provide tailored formulations, further fueling the trend of outsourcing. Recent trends indicate a growing focus on advanced technologies and methodologies in formulation development.

Companies are increasingly adopting automated systems and digital platforms to enhance efficiency and accuracy in formulation processes. This trend is particularly visible in the rise of artificial intelligence and machine learning applications that aid in predicting formulation behavior and outcomes, allowing for faster and more reliable results. Various opportunities in the US market can also be explored by considering the expanding biopharmaceutical sector, which is increasingly relying on specialized formulation services to develop complex biologics and biosimilars. Government initiatives promoting innovation in healthcare further encourage this exploration.

Furthermore, collaborations between pharmaceutical companies and CDMOs (Contract Development and Manufacturing Organizations) to streamline the formulation development process present significant opportunities. Overall, there is a clear trend toward increased collaboration in the US Formulation Development Outsourcing Market as firms seek strategic partnerships for enhanced innovation and flexibility. This evolving landscape highlights the importance of adapting to changing demands and utilizing new technologies to maintain competitiveness in the ever-evolving pharmaceutical industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**US Formulation Development Outsourcing Market Drivers**

**Growth in the Biopharmaceutical Sector**

Thanks to developments in the biopharmaceutical industry, the US formulation development outsourcing market is expanding significantly. The American Biomanufacturing and Biopharmaceuticals Association reports that more than 60% of the world's biopharmaceutical exports came from the United States, underscoring the importance of developing successful formulations. The US biopharmaceuticals market expanded at a compound annual growth rate (CAGR) of 8% between 2010 and 2020, demonstrating the extraordinary need for novel medication formulations that potentially improve patient outcomes.

In order to handle the complexity of these cutting-edge treatments, industry leaders like Amgen and Genentech have been at the forefront of using outsourcing to expedite their formulation development processes. This trend highlights the value of outsourcing formulation development in this quickly growing industry by improving scalability and speeding up time-to-market.

**Increase in Chronic Diseases**

The increasing prevalence of chronic diseases in the United States is driving the demand for innovative drug formulations within the US Formulation Development Outsourcing Market Industry. For instance, the Centers for Disease Control and Prevention (CDC) states that approximately 60% of adults in the US have at least one chronic disease, and this number is expected to rise. Consequently, pharmaceutical companies are expanding their portfolios to cater to these complex diseases, necessitating specialized formulation strategies. Companies such as Pfizer and Johnson & Johnson are ramping up their outsourcing efforts to meet the growing demand by leveraging specialized formulation development services.

This trend indicates a rising need for formulated drugs that enhance efficacy and patient compliance.

**Technological Innovations**

Technological advancements significantly impact the US Formulation Development Outsourcing Market Industry by improving efficiency and developing superior drug formulations. Automation technologies and Artificial Intelligence (AI) are increasingly utilized in formulation development processes, enabling companies to streamline operations and enhance productivity. A report from the US Food and Drug Administration shows that the incorporation of AI in drug development can reduce the time of research and development by up to 30%. Industry leaders like Eli Lilly and Merck are adopting these technologies through outsourcing partnerships, allowing them to focus on core competencies while enhancing formulation strategies.

This shift towards tech-driven solutions is crucial for maintaining competitive advantages in an evolving market landscape.

**US Formulation Development Outsourcing Market Segment Insights**

**Formulation Development Outsourcing Market Services Insights  **

The Services segment of the US Formulation Development Outsourcing Market is a crucial aspect of the industry, encompassing vital elements that drive operational efficiency and innovation in drug development. As the healthcare sector continues to evolve, the demand for specialized services in Pre Formulation and Formulation Optimization has grown significantly. Pre Formulation Services, which involve the early stages of drug development, play a pivotal role in determining the appropriate characteristics of the drug formulation, ensuring stability, and enhancing bioavailability.

This segment ensures that candidates are rigorously evaluated and refined before moving further along the development pipeline, which is essential for minimizing risks and optimizing costs. Additionally, Formulation Optimization focuses on tailoring formulations to achieve desired drug delivery characteristics, enhancing therapeutic efficacy. This process involves adjusting factors such as solubility, release rates, and delivery mechanisms, which are critical for improving patient outcomes. The integration of advanced technologies, such as artificial intelligence and data analytics, in these services is notable in the US, providing a competitive advantage by streamlining processes and facilitating quicker decision-making.

Alongside this, the increasing shift towards personalized medicine and biologics has intensified the focus on these services as companies strive to meet specific patient needs and regulatory requirements. The overall dynamics of the US healthcare landscape, including an aging population and rising chronic diseases, further amplify the significance of these services as they support the development of innovative therapies. Ultimately, the ongoing investments and advancements in the Services segment reflect a strong commitment towards enhancing the capabilities within the US Formulation Development Outsourcing Market, catering to the diverse needs of pharmaceutical clients.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Formulation Development Outsourcing Market Dosage Form Insights  **

The US Formulation Development Outsourcing Market for the Dosage Form segment is integral to the overall growth of the pharmaceutical industry. As the market continues to mature, various formats such as Injectable, Oral, Topical, and Inhaled are emerging as essential components in drug delivery systems. Injectable formulations are particularly significant given their ability to provide rapid therapeutic effects, which aligns with the increasing demand for biologics and monoclonal antibodies. Oral dosage forms maintain a substantial share of the market due to their convenience and patient compliance.

Topical formulations are gaining traction with the rise in chronic skin diseases and localized treatments. Inhaled formulations, driven by an increase in respiratory conditions, are essential as they offer targeted therapy and a quick onset of action. Additionally, other innovative formats are continuously being developed to enhance patient experience and drug efficacy. As the US maintains a robust Research and Development (R&D) environment, the emphasis on advanced formulation technologies and strong regulatory frameworks provides opportunities for further growth within these dosage forms, significantly contributing to the US Formulation Development Outsourcing Market data and statistics.

The diverse array of dosage forms highlights their importance in addressing patient needs, thus driving market growth and segmentation dynamics.

**Formulation Development Outsourcing Market Application Insights  **

The US Formulation Development Outsourcing Market within the Application segment displays significant growth, reflecting the evolving landscape of healthcare and pharmaceutical needs. This market includes various areas such as Oncology, Genetic Disorders, Neurology, Infectious Disease, Respiratory, Cardiovascular, and Others, with each area playing a pivotal role in addressing specific health challenges. Oncology, for instance, has gained immense traction due to the rising incidence of cancer, leading pharmaceutical companies to focus extensively on effective formulation strategies.

Genetic disorders are also becoming increasingly relevant as advancements in genomics spur innovations for targeted therapies. The Neurology segment is critical, considering the surging cases of neurological disorders, while Infectious Disease management remains a high priority, particularly in light of recent global health events. Additionally, the Respiratory and Cardiovascular segments are continually integrating new formulation techniques to combat prevalent health issues affecting a vast population. The diversity of these applications demonstrates the robust potential and lucrative opportunities within the US Formulation Development Outsourcing Market as companies seek tailored solutions to meet the unique demands of each therapeutic area.

Overall, this segment showcases a powerful intersection of technology, healthcare needs, and patient-centered approaches that signify its importance in the industry.

**Formulation Development Outsourcing Market End User Insights  **

The End User segmentation of the US Formulation Development Outsourcing Market highlights a diverse landscape that plays a crucial role in the development of pharmaceutical products. The Pharmaceutical and Biopharmaceutical sectors are at the forefront, largely due to their continuous need for innovative formulations and cost-effective outsourcing solutions. These industries drive a significant portion of the demand as they seek to enhance R&D productivity and reduce time-to-market for new drugs. Government entities also contribute, often seeking collaborations for strategic projects focused on public health initiatives and drug accessibility.

Academic Institutes play a pivotal role by fostering cutting-edge research and development, partnering with industry players to bridge the gap between academic insights and commercial applications. The diversity within the End User segment underscores its importance, with each category focusing on enhancing drug efficacy and safety while navigating regulatory complexities. Overall, the interplay between these entities not only sustains the growth of the market but also fuels innovation, addressing healthcare challenges within the US.

**US Formulation Development Outsourcing Market Key Players and Competitive Insights**

The US Formulation Development Outsourcing Market is characterized by a dynamic competitive landscape driven by increasing demand for efficient drug delivery systems and advancements in pharmaceutical technology. Companies in this market are focusing on enhancing their service offerings to cater to a wide range of clients, from small biotech firms to large pharmaceutical corporations. The rising trends in personalized medicine and biologics development are creating new opportunities for market players, prompting them to invest heavily in research and development.

Companies are also exploring strategic partnerships and collaborations to enhance their capabilities and broaden their service portfolios, allowing them to maintain a competitive edge in an evolving marketplace. Alcami Corporation stands out in the US Formulation Development Outsourcing Market due to its comprehensive suite of services that address various aspects of the drug development process. The company prides itself on its commitment to quality and regulatory compliance, which has bolstered its reputation among clients. Alcami offers tailored formulation development services, including analytical testing and manufacturing, making it a preferred partner for pharmaceutical companies seeking specialized solutions.

The company's extensive experience and expertise in different drug forms, such as injectables, oral solids, and topical formulations, enable it to meet diverse client needs effectively. Additionally, Alcami's strategic focus on building strong client relationships has facilitated its growth and presence in this competitive arena. Lonza Group is another key player in the US Formulation Development Outsourcing Market, known for its robust capabilities and innovative service offerings. The company's strengths lie in its comprehensive range of development and manufacturing services that cater primarily to the biotech and pharmaceutical sectors.

Lonza provides key services such as formulation development, clinical trial material production, and commercial manufacturing, ensuring a seamless transition from development to market. Its established presence in the US is complemented by its commitment to quality and compliance, which has led to successful collaborations with a variety of industry players. Lonza has pursued strategic mergers and acquisitions to expand its service capabilities and enhance its market reach, solidifying its position as a leading provider of formulation development services.

This strategic approach, along with a strong emphasis on client partnership, positions Lonza as a significant contributor to the evolving landscape of the US Formulation Development Outsourcing Market.

**Key Companies in the US Formulation Development Outsourcing Market Include**

**US Formulation Development Outsourcing Market Industry Developments**

In recent months, the US Formulation Development Outsourcing Market has seen several significant developments. In September 2023, Catalent announced plans to expand its manufacturing capabilities in Indiana, which aims to enhance its formulation services, addressing increasing demand from the pharmaceutical sector. Additionally, in August 2023, Lonza Group highlighted its collaboration with WuXi AppTec to strengthen their combined offerings in drug development, leveraging both companies’ expertise in formulation development. October 2022 marked Aenova’s acquisition of a facility in California to boost its capacity for oral dosage forms, thereby solidifying its presence in the U.S. market.

The growth in this sector is also reflected in increasing market valuations, as Alcami Corporation and Thermo Fisher Scientific report substantial revenue increases due to heightened outsourcing activities amid a growing pipeline of biotech products.

Moreover, Evonik Industries and Fujifilm Diosynth Biotechnologies are focusing on innovations in bioprocessing and formulation technologies to meet the stringent demands of regulatory environments in the U.S. The overall trend indicates a robust demand for outsourcing services as pharmaceutical companies seek to streamline their development processes while ensuring compliance and quality.

**Formulation Development Outsourcing Market Segmentation Insights**

## Market Drivers

### Growing Regulatory Pressures

The formulation development-outsourcing market is also shaped by growing regulatory pressures. As regulatory bodies impose stricter guidelines on product safety and efficacy, companies are compelled to ensure compliance throughout the formulation process. This trend is particularly pronounced in the pharmaceutical and food industries, where adherence to regulations is paramount. In 2025, it will be projected that compliance-related costs will account for nearly 15% of total R&D expenditures. Consequently, many firms are turning to outsourcing partners with expertise in regulatory affairs to navigate these complexities, thereby driving growth in the formulation development-outsourcing market.

### Expansion of Biopharmaceuticals

The expansion of the biopharmaceutical sector is a significant driver of the formulation development-outsourcing market. As biopharmaceuticals gain traction due to their targeted therapeutic effects, the need for specialized formulation services tailored to biologics is increasing. This sector is expected to grow at a CAGR of around 10% through 2025, creating substantial opportunities for outsourcing firms that can provide the necessary expertise in biologics formulation. The complexity of these products often necessitates collaboration with experienced partners, thereby propelling the growth of the formulation development-outsourcing market.

### Increased Focus on Sustainability

Sustainability is becoming a critical driver in the formulation development-outsourcing market. Companies are increasingly seeking eco-friendly formulations that align with consumer preferences for sustainable products. This shift is prompting outsourcing partners to innovate and develop formulations that utilize renewable resources and minimize environmental impact. In 2025, it will be anticipated that the market for sustainable formulations will account for approximately 25% of the overall formulation development outsourcing market. As firms strive to enhance their sustainability profiles, the demand for specialized outsourcing services that can deliver these formulations is likely to rise.

### Rising Complexity of Formulations

The formulation development-outsourcing market is experiencing a notable increase in the complexity of formulations required by clients. As industries such as pharmaceuticals and cosmetics evolve, the demand for sophisticated formulations that meet specific therapeutic or aesthetic needs intensifies. This complexity often necessitates specialized expertise and advanced technologies, prompting companies to outsource these tasks to experts. In 2025, the market will be projected to grow at a CAGR of approximately 8.5%, driven by the need for innovative solutions that in-house teams may struggle to provide. Consequently, outsourcing becomes a strategic choice for firms aiming to stay competitive in a rapidly changing landscape.

### Technological Advancements in R&D

Technological advancements are significantly influencing the formulation development-outsourcing market. The integration of artificial intelligence, machine learning, and high-throughput screening technologies is streamlining the research and development processes. These innovations enable faster and more efficient formulation development, allowing companies to bring products to market more quickly. In 2025, it will be estimated that around 30% of companies in the sector will leverage these technologies, enhancing their ability to meet client demands. As a result, outsourcing partners that adopt these technologies are likely to gain a competitive edge, further driving the growth of the formulation development-outsourcing market.

## Future Outlook

The [Formulation Development Outsourcing Market](https://www.marketresearchfuture.com/reports/formulation-development-outsourcing-market-10387) is projected to grow at a 7.51% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for specialized services.

**New opportunities:**

- Investment in AI-driven formulation optimization tools. Expansion of contract manufacturing capabilities for niche markets. Development of sustainable and eco-friendly formulation solutions.

By 2035, the market is expected to achieve robust growth, positioning itself as a leader in innovation.

## Segment Insights

### By Services: Pre Formulation Services (Largest) vs. Formulation Optimization (Fastest-Growing)

In the US formulation development-outsourcing market, the distribution of market share among segment values reveals that Pre Formulation Services hold a significant portion, reflecting their critical role in the initial stages of product development. This segment includes essential activities such as stability testing and excipient selection, which are foundational for successful formulation outcomes. On the other hand, Formulation Optimization is emerging as the fastest-growing segment, driven by increasing demand for customized solutions and efficiency in drug development processes. Companies are focusing on optimizing formulations to enhance bioavailability and reduce development times, highlighting the dynamic nature of this segment as it adapts to evolving market needs.

Pre Formulation Services (Dominant) vs. Formulation Optimization (Emerging)

Pre Formulation Services are characterized by their foundational importance in the formulation development process, ensuring that the basic characteristics of a product align with regulatory and market requirements. This segment encompasses critical testing and analysis that assist in developing stable and effective formulations. In contrast, Formulation Optimization is gaining momentum, driven by technological advancements and demands for faster time-to-market. This segment focuses on refining existing formulations to improve their efficacy and delivery, appealing to a broader range of applications across therapeutics and consumer products. The agility and innovation seen in Formulation Optimization are setting it up as a key player in the ever-evolving landscape of the formulation development space.

### By Dosage Form: Injectable (Largest) vs. Oral (Fastest-Growing)

The US formulation development-outsourcing market exhibits a diverse distribution of dosage forms, with injectables holding the largest share. Their popularity is driven by the increasing need for biologics and complex drugs that require precise delivery systems. Oral dosage forms follow, fueled by the convenience and patient compliance that oral medications provide, although they lag behind injectables in overall market impact. Growth trends indicate that while injectables remain dominant due to their established efficacy in therapeutic areas, oral dosage forms are emerging rapidly. This growth is propelled by advancements in formulation techniques enhancing bioavailability, alongside a growing preference for oral treatments over injections. The inhaled and topical segments also show potential, catering to specialized applications but with more modest growth rates compared to oral forms.

Injectable: Dominant vs. Oral: Emerging

Injectables have firmly established themselves as the dominant dosage form in the market, primarily due to their effectiveness in delivering biologic therapies and [vaccines](../../../reports/middle-east-and-africa-hpv-vaccines-market-16185). They cater to a range of therapeutic areas and require sophisticated technology for formulation and delivery. In contrast, oral dosage forms are emerging rapidly, driven by innovations that enhance their formulation and patient adherence. These forms are not only more convenient for patients but are also being developed to improve bioavailability and therapeutic outcomes. The ongoing research into better excipients and delivery mechanisms is poised to enhance the competitiveness of oral forms, while injectables maintain a strong foothold due to their extensive therapeutic applications.

### By Application: Oncology (Largest) vs. Neurology (Fastest-Growing)

The market share distribution among various application segments highlights Oncology as the dominant area within the US formulation development-outsourcing market. This segment commands a significant share due to the increasing incidence of cancer and the rising demand for innovative therapies. Other segments, such as Infectious Disease and Respiratory, also contribute to the market but have relatively smaller shares. Growth trends indicate that Neurology is the fastest-growing segment, driven by advancements in research and technology. The increasing prevalence of neurological disorders, such as Alzheimer's and Parkinson's disease, propels demand for effective treatment solutions. Moreover, rising investments in R&D and collaborations among biotech firms and academic institutions are facilitating innovation in this sector, further enhancing its growth prospects.

Oncology (Dominant) vs. Neurology (Emerging)

Oncology remains the dominant segment within the US formulation development-outsourcing market, characterized by extensive research investment and a robust pipeline of therapies. The segment benefits from government initiatives to support cancer research and development. Conversely, Neurology, though emerging, is gaining traction with a focus on addressing unmet medical needs. The increasing acknowledgment of neurological diseases and the growing aging population are pivotal factors driving its expansion. Companies are now prioritizing innovative solutions tailored to neurological disorders, making Neurology a promising area for future growth and attracting heightened interest from investors and stakeholders.

### By End User: Pharmaceutical and Biopharmaceutical (Largest) vs. Academic Institutes (Fastest-Growing)

In the US formulation development-outsourcing market, the Pharmaceutical and Biopharmaceutical segment holds the largest market share, as these industries continuously seek advanced formulation services to accelerate drug development and ensure regulatory compliance. This is in stark contrast to Academic Institutes, which, while smaller in share, are rapidly gaining traction due to increasing collaborations with biotech firms and a heightened focus on research and development. Growth trends in this segment are being driven by factors such as innovation in drug formulation technologies and a surge in demand for personalized medicine. Pharmaceutical companies are increasingly outsourcing formulation development to focus on core competencies, while academic institutions are emerging as vital players by fostering partnerships that enhance their research capabilities, leading to significant advancements in therapeutic development.

Pharmaceutical and Biopharmaceutical (Dominant) vs. Academic Institutes (Emerging)

The Pharmaceutical and Biopharmaceutical segment is characterized by its extensive resources and advanced technology capabilities, enabling rapid drug formulation and optimized delivery systems. These companies have established strong relationships with contract research organizations, which allows them to leverage external expertise efficiently. In contrast, Academic Institutes, while currently smaller in market share, are recognized for their innovative research and development initiatives. They actively contribute to the discovery of new drug candidates and are increasingly collaborating with industry partners to translate research into viable products. As they shift towards commercialization, their role in the US formulation development-outsourcing market is expected to grow, making them a key player in shaping future trends in pharmaceutical advancements.

## Competitive Benchmarking

The formulation development-outsourcing market is characterized by a dynamic competitive landscape, driven by increasing demand for innovative drug formulations and the need for cost-effective solutions. Key players such as Catalent (US), Lonza Group (CH), and Boehringer Ingelheim (DE) are strategically positioned to leverage their extensive capabilities in drug development and manufacturing. Catalent (US) focuses on enhancing its service offerings through technological advancements and strategic partnerships, while Lonza Group (CH) emphasizes its commitment to sustainability and operational efficiency. Boehringer Ingelheim (DE) is actively pursuing mergers and acquisitions to expand its portfolio and enhance its market presence, collectively shaping a competitive environment that prioritizes innovation and operational excellence. In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The market appears moderately fragmented, with several key players exerting significant influence. This structure allows for a diverse range of services and capabilities, fostering competition that drives innovation and efficiency across the sector. In October 2025, Catalent (US) announced a strategic partnership with a leading biotech firm to enhance its capabilities in biologics development. This collaboration is expected to bolster Catalent's position in the rapidly growing biologics market, reflecting a broader trend towards specialization and innovation in formulation development. The partnership may enable Catalent to leverage advanced technologies and expertise, thereby enhancing its service offerings and competitive edge. In September 2025, Lonza Group (CH) unveiled a new state-of-the-art facility in the US dedicated to the production of advanced drug delivery systems. This investment underscores Lonza's commitment to meeting the evolving needs of its clients and enhancing its manufacturing capabilities. The facility is anticipated to significantly increase production capacity, allowing Lonza to better serve its growing customer base and respond to market demands more effectively. In August 2025, Boehringer Ingelheim (DE) completed the acquisition of a prominent formulation development company, further solidifying its position in the market. This acquisition is likely to enhance Boehringer Ingelheim's capabilities in drug formulation and development, enabling it to offer a more comprehensive suite of services to its clients. The move reflects a strategic focus on expanding its portfolio and enhancing its competitive positioning in the formulation development space. As of November 2025, current trends in the formulation development-outsourcing market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into operations. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a focus on innovation, technology, and supply chain reliability. This transition may redefine how companies position themselves in the market, emphasizing the importance of agility and responsiveness to client needs.

## Recent News & Developments

In recent months, the US Formulation Development Outsourcing Market has seen several significant developments. In September 2023, Catalent announced plans to expand its manufacturing capabilities in Indiana, which aims to enhance its formulation services, addressing increasing demand from the pharmaceutical sector. Additionally, in August 2023, Lonza Group highlighted its collaboration with WuXi AppTec to strengthen their combined offerings in drug development, leveraging both companies’ expertise in formulation development. October 2022 marked Aenova’s acquisition of a facility in California to boost its capacity for oral dosage forms, thereby solidifying its presence in the U.S. market.

The growth in this sector is also reflected in increasing market valuations, as Alcami Corporation and Thermo Fisher Scientific report substantial revenue increases due to heightened outsourcing activities amid a growing pipeline of biotech products.

Moreover, Evonik Industries and Fujifilm Diosynth Biotechnologies are focusing on innovations in bioprocessing and formulation technologies to meet the stringent demands of regulatory environments in the U.S. The overall trend indicates a robust demand for outsourcing services as pharmaceutical companies seek to streamline their development processes while ensuring compliance and quality.

## Report Scope

| MARKET SIZE 2024 | 2300.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2472.73(USD Million) |
| MARKET SIZE 2035 | 5100.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.51% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Lonza Group (CH), Catalent (US), Boehringer Ingelheim (DE), Recipharm (SE), Famar (FR), Siegfried Holding (CH), Alcami (US), Aenova Group (DE), Vetter Pharma (DE) |
| Segments Covered | Services, Dosage Form, Application, End User |
| Key Market Opportunities | Integration of advanced technologies enhances efficiency in the formulation development-outsourcing market. |
| Key Market Dynamics | Rising demand for innovative formulations drives competitive dynamics in the formulation development-outsourcing market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US formulation development-outsourcing market?**
A: The market valuation was $2300.0 Million in 2024.

**Q: What is the projected market size for the US formulation development-outsourcing market by 2035?**
A: The market is projected to reach $5100.0 Million by 2035.

**Q: What is the expected CAGR for the US formulation development-outsourcing market during the forecast period 2025 - 2035?**
A: The expected CAGR is 7.51% from 2025 to 2035.

**Q: Which companies are considered key players in the US formulation development-outsourcing market?**
A: Key players include Lonza Group, Catalent, Boehringer Ingelheim, Recipharm, and others.

**Q: What are the main service segments in the US formulation development-outsourcing market?**
A: Main service segments include Pre Formulation Services and Formulation Optimization.

**Q: What is the valuation range for Pre Formulation Services in the US formulation development-outsourcing market?**
A: The valuation for Pre Formulation Services ranges from $800.0 Million to $1800.0 Million.

**Q: What dosage forms are included in the US formulation development-outsourcing market?**
A: Dosage forms include Injectable, Oral, Topical, Inhaled, and Others.

**Q: What is the projected valuation for Oral dosage forms in the US formulation development-outsourcing market?**
A: The projected valuation for Oral dosage forms ranges from $1200.0 Million to $2700.0 Million.

**Q: Which applications are driving growth in the US formulation development-outsourcing market?**
A: Applications driving growth include Oncology, Neurology, and Infectious Disease.

**Q: What is the expected valuation for the Government end-user segment in the US formulation development-outsourcing market?**
A: The expected valuation for the Government end-user segment ranges from $690.0 Million to $1500.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-formulation-development-outsourcing-market-18021*